Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

IVIG therapy was linked to hair regrowth in two patients with hair loss, but it's not recommended due to its risks and costs.

Androgen therapy might help some women with low libido, but it has risks and should be used carefully.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Finasteride affects offspring's antioxidant enzymes in epididymis, possibly disrupting sperm maturation.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Taking DHEA for a year is generally safe for postmenopausal women but may cause acne and more facial hair without improving metabolism or aging.

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

Artificial skin development has challenges, but new materials and understanding cell behavior could improve tissue repair. Also, certain growth factors and hydrogel technology show promise for advanced skin replacement therapies.

Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.

Short-term testosterone therapy in women seems safe with few mild side effects, but long-term effects need more research.

Hormone therapy may increase migraines in transgender women and decrease them in transgender men; more research is needed on migraine management in transgender individuals.

Updated treatments for female hair loss include minoxidil, antiandrogens, hair transplants, and light therapy.

Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

DHEA may help with sexual function when used intravaginally by menopausal women but is similar to hormone therapy in other aspects and might cause more side effects like acne and hair loss.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

Hormonal therapy changes skin and hair in transgender patients, who need better researched dermatologic care.

The document summarizes medical findings on topics like heart rhythm treatment, sleep apnea therapy, and various health conditions and treatments.

The document concludes that Nonclassic Congenital Adrenal Hyperplasia requires personalized treatment plans to manage symptoms and fertility, with glucocorticoids being a common therapy.

Sleep, testosterone levels, and a specific enzyme activity affect skin oil production in women.

Testosterone, progesterone, and levonorgestrel change enzyme levels related to fat production in hamster skin, which could affect skin oil and acne.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Stem cell therapies show promise for treating various diseases but face challenges in clinical use and require better monitoring techniques.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

17α-estradiol is a safe estrogen that might protect the brain and doesn't cause feminization, needing more research for treating brain diseases.